title: HIV vaccine: hopes and hurdles.
abstract: The AIDS vaccine development effort has already been facing various scientific and economic challenges. The fundamental challenge resides at the level of understanding the basic biology of HIV-1 infection and an effective antiviral immune response. There is a need to design immunogens that can elicit cross-clade neutralizing antibodies (NAbs) along with effective T-cell responses against a wide variety of primary HIV isolates. We must exploit the capabilities of the vaccine-elicited cytotoxic T cells and the NAb responses in controlling HIV-1 replication. A coordinated approach is required to understand the intricacies involved in the basic immune responses against HIV infection as well as the cross-clade effectiveness of an AIDS vaccine.
authors: Laboratory of Neurovirology & Inflammation Biology, Section of Infectious Diseases, Centre for Cellular and Molecular Biology (CCMB), Council of Scientific and Industrial Research (CSIR), India.
authors: Chintan
authors: C
authors: Chhatbar
authors: Ritu
authors: R
authors: Mishra
authors: Ashish
authors: A
authors: Kumar
authors: Sunit Kumar
authors: SK
authors: Singh
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use; D055808:Drug Discovery; D015483:HIV Antibodies / Q000276:immunology / Q000502:physiology; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology / Q000502:physiology; D006801:Humans
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies